Susceptibility to SARS-CoV-2 of Cell Lines and Substrates Commonly Used to Diagnose and Isolate Influenza and Other Viruses
Li Wang, Xiaoyu Fan, Gaston Bonenfant, Dan Cui, Jaber Hossain, Nannan Jiang, Gloria Larson, Michael Currier, Jimma Liddell, Malania Wilson, Azaibi Tamin, Jennifer Harcourt, Jessica Ciomperlik-Patton, Hong Pang, Naomi Dybdahl-Sissoko, Ray Campagnoli, Pei-Yong Shi, John Barnes, Natalie J. Thornburg, David E. Wentworth, and Bin Zhou
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L. Wang, X. Fan, J. Hossain, M. Currier, M. Wilson, A. Tamin, J. Harcourt, J. Ciomperlik-Patton, H. Pang, N. Dybdahl-Sissoko, R. Campagnoli, J. Barnes, N.J. Thornburg, D.E. Wentworth, B. Zhou); Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA (G. Bonenfant, N. Jiang, G. Larson); Battelle Memorial Institute, Atlanta, Georgia, USA (D. Cui, J. Liddell); University of Texas Medical Branch, Galveston, Texas, USA (P.-Y. Shi)
Figure 2. Varied severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral replication kinetics in commercially sourced cell lines in study of susceptibility to SARS-CoV-2 of cell lines and substrates used to diagnose and isolate influenza and other viruses. Data are mean of n = 4 +SD. TCID50, median tissue culture infectious dose.
Page created: February 24, 2021
Page updated: April 20, 2021
Page reviewed: April 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.